The cost and value of cancer drugs - are new innovations outpacing our ability to pay?
Cancer drug expenditures have been increasing significantly in countries around the world. A recent paper in the IJHPR provides new knowledge and insights into this global phenomenon by analyzing how it is playing out in an Israeli health plan with over two million members, whose state-of-the-art information systems provide an opportunity to explore these changes in a comprehensive, detailed and reliable manner. There is a wide variation in both the cost-effectiveness and the budget impact of individual drugs. These issues also vary when analyzing drugs in other countries due to differential pricing mechanisms. In addition to drug expenditure, the overall cost of cancer care is increasing, partly due to expenditures on non-pharmacologic treatments and diagnostic testing. With the arrival of new therapies, the future of cancer care is exciting. However, there will be many challenges ahead with regard to the ability to pay for such innovations. In this commentary we discuss the current problems and anticipate the future challenges.
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel ; Winship Cancer Institute, Emory University, Atlanta, GA USA.
Daniel A
DA
Goldstein
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel ; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Salomon M
SM
Stemmer
Davidoff Cancer Center, Rabin Medical Center, Petach Tikvah, Israel ; Ben Gurion University of the Negev, Beer Sheva, Israel.
Noa
N
Gordon
Expert Rev Anticancer Ther. 2016;16(4):383-90
26943236
Health Syst Transit. 2015 ;17 (6):1-212
27050102
J Clin Oncol. 2015 Apr 1;33(10):1112-8
25691669
Isr J Health Policy Res. 2016 Sep 15;5:37
27651890
J Clin Oncol. 2016 Mar 20;34(9):980-6
26811521
PLoS Med. 2016 May 31;13(5):e1002032
27243629
Lancet Oncol. 2012 Mar;13(3):239-46
22285168
J Clin Oncol. 2016 Mar 20;34(9):902-9
26351332
Lancet Oncol. 2016 Jan;17(1):39-47
26670089
N Engl J Med. 2015 Nov 5;373(19):1803-13
26406148
Oncologist. 2016 Aug;21(8):907-9
27384235
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
N Engl J Med. 2013 Jun 20;368(25):2385-94
23724913
N Engl J Med. 2014 Mar 27;370(13):1189-97
24670165
N Engl J Med. 2015 Jul 9;373(2):123-35
26028407
Health Aff (Millwood). 2013 Jun;32(6):1143-52
23676531
JAMA Intern Med. 2016 Jan;176(1):65-73
26595724
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
JAMA Oncol. 2015 Sep;1(6):729-30
26182331